131I/123I-metaiodobenzylguanidine (mIBG) Scintigraphy: Procedure Guidelines for Tumour Imaging

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2010 Jul 21

PMID 20644928

Citations 65

Authors

Emilio Bombardieri

Francesco Giammarile

Cumali Aktolun

Richard P Baum

Angelika Bischof Delaloye

Lorenzo Maffioli

Roy Moncayo

Luc Mortelmans

Giovanna Pepe

Sven N Reske

Maria R Castellani

Arturo Chiti

Affiliations

Soon will be listed here.

Abstract

The aim of this document is to provide general information about mIBG scintigraphy in cancer patients. The guidelines describe the mIBG scintigraphy protocol currently used in clinical routine, but do not include all existing procedures for neuroendocrine tumours. The guidelines should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary from one country to another and from one medical institution to another. The present guidelines have been prepared for nuclear medicine physicians and intend to offer assistance in optimizing the diagnostic information that can currently be obtained from mIBG scintigraphy. The corresponding guidelines of the Society of Nuclear Medicine (SNM) and the Dosimetry, Therapy and Paediatric Committee of the EANM have been taken into consideration, and partially integrated into this text. The same has been done with the most relevant literature on this topic, and the final result has been discussed within a group of distinguished experts.

Citing Articles

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma.

Sanchez-Vano R, Balaguer J, Borrego-Dorado I, Esteban-Figueruelo A, Gamez C, Hladun R Clin Transl Oncol. 2024; .

PMID: 39508974 DOI: 10.1007/s12094-024-03755-3.

Thai national guideline for nuclear medicine investigation in movement disorders: Nuclear medicine society of Thailand, the neurological society of Thailand, and Thai medical physicist society collaboration.

Kaewchur T, Khiewvan B, Chamroonrat W, Lolekha P, Phokaewvarangkul O, Thientunyakit T Asia Ocean J Nucl Med Biol. 2024; 12(2):86-107.

PMID: 39050239 PMC: 11263770. DOI: 10.22038/AOJNMB.2023.75619.1531.

Accuracy of patient-specific I-131 dosimetry using hybrid whole-body planar-SPECT/CT I-123 and I-131 imaging.

Morphis M, van Staden J, du Raan H, Ljungberg M, Sjogreen Gleisner K EJNMMI Phys. 2024; 11(1):50.

PMID: 38898326 PMC: 11187057. DOI: 10.1186/s40658-024-00657-9.

3-[F]Fluoro--hydroxyphenethylguanidine (3-[F]pHPG) PET-A Novel Imaging Modality for Paraganglioma.

Else T, Wong K, Frey K, Brooks A, Viglianti B, Raffel D J Endocr Soc. 2024; 8(6):bvae049.

PMID: 38617812 PMC: 11010306. DOI: 10.1210/jendso/bvae049.

Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.

Theis H, Pavese N, Rektorova I, van Eimeren T J Parkinsons Dis. 2024; 14(s2):S353-S365.

PMID: 38339941 PMC: 11492013. DOI: 10.3233/JPD-230385.

References

Adams S, Baum R, Rink T, Usadel K, Hor G . Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998; 25(1):79-83. DOI: 10.1007/s002590050197. View

Meyer-Rochow G, Schembri G, Benn D, Sywak M, Delbridge L, Robinson B . The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2009; 17(2):392-400. DOI: 10.1245/s10434-009-0850-5. View

Boubaker A, Bischof Delaloye A . Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med. 2003; 47(1):31-40. View

Zuetenhorst J, Hoefnageli C, Boot H, Valdes Olmos R, Taal B . Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun. 2002; 23(8):735-41. DOI: 10.1097/00006231-200208000-00006. View

Taal B, Hoefnagel C, Valdes Olmos R, Boot H . Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer. 1996; 32A(11):1924-32. DOI: 10.1016/0959-8049(96)00241-9. View

Suc A, Lumbroso J, Rubie H, Hattchouel J, Boneu A, Rodary C . Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer. 1996; 77(4):805-11. DOI: 10.1002/(sici)1097-0142(19960215)77:4<805::aid-cncr29>3.0.co;2-3. View

Taggart D, Han M, Quach A, Groshen S, Ye W, Villablanca J . Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009; 27(32):5343-9. PMC: 2773221. DOI: 10.1200/JCO.2008.20.5732. View

Leung A, Shapiro B, HATTNER R, Kim E, de Kraker J, Ghazzar N . Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med. 1997; 38(9):1352-7. View

Lynn M, Shapiro B, Sisson J, Swanson D, Mangner T, Wieland D . Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med. 1984; 25(4):436-40. View

10.

Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B . Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009; 94(12):4757-67. PMC: 2795662. DOI: 10.1210/jc.2009-1248. View

11.

Rubello D, Bui C, Casara D, Gross M, Fig L, Shapiro B . Functional scintigraphy of the adrenal gland. Eur J Endocrinol. 2002; 147(1):13-28. DOI: 10.1530/eje.0.1470013. View

12.

Sharp S, Shulkin B, Gelfand M, Salisbury S, Furman W . 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237-43. DOI: 10.2967/jnumed.108.060467. View

13.

Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A . Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol. 1999; 21(1):13-8. DOI: 10.1097/00043426-199901000-00004. View

14.

Solanki K, Bomanji J, Moyes J, Mather S, Trainer P, Britton K . A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992; 13(7):513-21. DOI: 10.1097/00006231-199207000-00006. View

15.

Stabin M, Gelfand M . Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med. 1998; 42(2):93-112. View

16.

Okuyama C, Sakane N, Yoshida T, Shima K, Kurosawa H, Kumamoto K . (123)I- or (125)I-metaiodobenzylguanidine visualization of brown adipose tissue. J Nucl Med. 2002; 43(9):1234-40. View

17.

Messina J, Cheng S, Franc B, Charron M, Shulkin B, To B . Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006; 47(7):865-74. DOI: 10.1002/pbc.20777. View

18.

Gordon I, Peters A, Gutman A, Morony S, Pritchard J . Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans. J Nucl Med. 1990; 31(2):129-34. View

19.

Feggi L, Degli Uberti E, Pansini G, Transforini G, Prandini N, Ambrosio M . Pitfalls in scintigraphic detection of neuroendocrine tumours. Eur J Nucl Med. 1992; 19(3):214-8. DOI: 10.1007/BF00173284. View

20.

Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y . Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999; 6(3):119-24. DOI: 10.1046/j.1442-2042.1999.06310.x. View